CVR

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DOMA, LABP, FUSN, CBNK

Retrieved on: 
Tuesday, April 9, 2024
AbbVie, Empire, AstraZeneca, Integration, Sale, Capital, DOMA, CBNK, CVR, Security (finance)

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.

Key Points: 
  • NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
  • Under the terms of the agreement, DOMA shareholders are expected to receive $6.29 in cash per share they own.
  • Capital Bancorp, Inc. (Nasdaq: CBNK ), relating to its proposed merger with Integrated Financial Holdings, Inc.
  • Under the terms of the agreement, CBNK shareholders are estimated to receive $5.36 in cash and 1.115 shares of Capital common stock per share they own.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)

Retrieved on: 
Monday, April 1, 2024
AbbVie, AstraZeneca, THL, ABBV, IPO, Thomas H. Lee Partners, Brodsky, AZN, CVR, Security (finance)

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, AdTheorent will be acquired by Cadent, LLC (“Cadent”).
  • The Company’s common stockholders will receive cash consideration of $3.21 per share.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

Pineapple Energy Announced CVR Agreement extended to December 31, 2024

Retrieved on: 
Friday, March 29, 2024
Equiniti, Contingent value rights, Solar energy, CSI, CVR, Security (finance)

MINNETONKA, Minn., March 28, 2024 (GLOBE NEWSWIRE) -- Pineapple Energy Inc. (NASDAQ: PEGY), a leading provider of sustainable solar energy and back-up power to households and small businesses, today announced CVR agreement extended to December 31, 2024.

Key Points: 
  • MINNETONKA, Minn., March 28, 2024 (GLOBE NEWSWIRE) -- Pineapple Energy Inc. (NASDAQ: PEGY), a leading provider of sustainable solar energy and back-up power to households and small businesses, today announced CVR agreement extended to December 31, 2024.
  • The CVRs were distributed, pursuant to a Contingent Value Rights Agreement (“CVR Agreement”) between Pineapple Energy, the CVR Holders’ Representative, and Equiniti Trust Company.
  • At the time of the merger, it was contemplated that the disposition of CSI’s pre-merger assets would be completed within two years following the merger and the CVR Agreement was scheduled to expire on March 28, 2024.
  • As a result, Pineapple Energy, Equiniti and the CVR Holders’ Representative have agreed to extend the term of the CVR Agreement to December 31, 2024.

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024
Hepatitis, KPMG, GNI, Cirrhosis, Patient, Chronic obstructive pulmonary disease, Sale, Coagulopathy, Ernst & Young, Idiopathic pulmonary fibrosis, Fibrosis, Therapy, COPD, Marketing, Partnership, Arthur Andersen, Audit committee, SAN, Safety, CVR, CHB, Fatty liver disease, Prevalence, Pharmacy, Hospital, Research, Acquisition, TGF, Pirfenidone, GAAP, Toxicity, Inflammation, Accounting, Entecavir, Loss, Orthostatic hypertension, IPF, Partner, NASH, Category 1, Pharmaceutical industry

Mr. Nussbaum brings nearly four decades of experience in accounting and financial reporting in the U.S. and Asia Pacific Region.

Key Points: 
  • Mr. Nussbaum brings nearly four decades of experience in accounting and financial reporting in the U.S. and Asia Pacific Region.
  • In October 2023, Gyre (formerly known as Catalyst Biosciences, Inc. (“Catalyst”)) completed the previously announced business combination with GNI Group Ltd. (“GNI”) and related entities.
  • In October 2023, Gyre Pharmaceuticals completed enrollment of its Phase 3 trial in patients with CHB-associated liver fibrosis in the PRC.
  • Use of Non-GAAP Financial Measures by Gyre Therapeutics, Inc.
    Gyre reports financial results in accordance with accounting principles generally accepted in the United States (“GAAP”).

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)

Retrieved on: 
Monday, March 25, 2024
AbbVie, AstraZeneca, THL, ABBV, Sale, Base, IPO, Thomas H. Lee Partners, Brodsky, AZN, CVR, Security (finance)

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the Merger Agreement, Agiliti will be acquired by Thomas H. Lee Partners, L.P. (“THL”).
  • Under the terms of the agreement, Landos Biopharma will be acquired by AbbVie Inc. (“AbbVie”) (NYSE - ABBV).
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

Retrieved on: 
Tuesday, March 19, 2024
KNTE, Cash, Acquisition, Treasury, Sale, CVR, Security (finance)

On March 4, 2024, XOMA commenced a tender offer to acquire all outstanding shares of Kinnate common stock (“the Offer”).

Key Points: 
  • On March 4, 2024, XOMA commenced a tender offer to acquire all outstanding shares of Kinnate common stock (“the Offer”).
  • Pursuant to the terms of the Merger Agreement, based upon Kinnate’s estimated calculation of cash, net of transaction costs, wind-down costs and other liabilities at closing, the additional cash amount has been determined to be the maximum $0.2527 per share.
  • Therefore, the Cash Amount that Kinnate stockholders will receive in the Offer is $2.5879 per share.
  • As previously announced, Kinnate stockholders holding approximately 46% of Kinnate common stock have signed support agreements to tender their shares in the Offer prior to the expiration date and support the merger.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCT

Retrieved on: 
Tuesday, March 19, 2024
AstraZeneca, Sale, Base, Lemon Popsicle, Brodsky, AZN, Society, CVR, Security (finance)

BALA CYNWYD, Pa., March 19, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., March 19, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, Societal will be acquired by CoreRx, Inc. (“CoreRx”) for $1.10 per share in cash.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – DOOR, FREE, INBX, TAST

Retrieved on: 
Monday, March 18, 2024
Empire, TAST, Sale, FREE, Owens Corning, Carrols Restaurant Group, CVR, Security (finance)

Under the terms of the agreement, DOOR shareholders are expected to receive $133.00 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, DOOR shareholders are expected to receive $133.00 in cash per share they own.
  • Under the terms of the agreement, FREE shareholders are expected to receive $4.875 in cash per share they own.
  • Under the terms of the agreement, TAST shareholders are expected to receive $9.55 in cash per share they own.
  • Before you hire a law firm, you should talk to a lawyer and ask:
    Do you recover money for shareholders?

Homology Medicines Declares Distribution to Common Stockholders

Retrieved on: 
Monday, March 18, 2024
Failure, 600 (number), Growth, Form, Risk, COVID-19, Form S-4, XXV, Security (finance), Nature, XV, Annual report, File, CVR

BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held by such stockholder as of such record date.

Key Points: 
  • BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held by such stockholder as of such record date.
  • The payment date for such distribution is expected to be March 27, 2024 (three business days after the expected closing of the merger on March 22, 2024).
  • Certain statements contained in this filing may be considered forward-looking statements within the meaning of the U.S.
  • Homology can give no assurance that the conditions to the proposed transaction will be satisfied.

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – KAMN, JNPR, INBX

Retrieved on: 
Wednesday, March 13, 2024
Empire, Hewlett-Packard, Investment management, JNPR, Sale, KAMN, CVR, Security (finance)

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.

Key Points: 
  • NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
  • Under the terms of the agreement, KAMN shareholders are expected to receive $46.00 in cash per share they own.
  • Under the terms of the agreement, JNPR shareholders are expected to receive $40.00 in cash per share they own.
  • Before you hire a law firm, you should talk to a lawyer and ask:
    Do you recover money for shareholders?